Anectine® (Succinylcholine Chloride Injection, USP)

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

SUCCINYLCHOLINE CHLORIDE (UNII: I9L0DDD30I) (SUCCINYLCHOLINE - UNII:J2R869A8YF)

から入手可能:

Sandoz Inc

投与経路:

INTRAVENOUS

処方タイプ:

PRESCRIPTION DRUG

適応症:

Succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia, skeletal muscle myopathies, and known hypersensitivity to the drug. It is also contraindicated in patients after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest (see WARNINGS ). The risk of hyperkalemia in these patients increases over time and usually peaks at 7 to 10 days after the injury. The risk is dependent on the extent and location of the injury. The precise time of onset and the duration of the risk period are not known.

製品概要:

For immediate injection of single doses for short procedures: ANECTINE (succinylcholine chloride) Injection, 20 mg in each mL. Multiple-dose vials of 10 mL, box of 10 vials (NDC 0781-3009-95). Store in refrigerator at 2° to 8°C (36° to 46°F). The multi-dose vials are stable for up to 14 days at room temperature without significant loss of potency.

認証ステータス:

New Drug Application

製品の特徴

ANECTINE- SUCCINYLCHOLINE CHLORIDE INJECTION, SOLUTION
SANDOZ INC
----------
ANECTINE® (SUCCINYLCHOLINE CHLORIDE INJECTION, USP)
WARNING
RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS
There have been rare reports of acute rhabdomyolysis with hyperkalemia
followed by ventricular
dysrhythmias, cardiac arrest, and death after the administration of
succinylcholine to apparently
healthy children who were subsequently found to have undiagnosed
skeletal muscle myopathy,
most frequently Duchenne's muscular dystrophy.
This syndrome often presents as peaked T-waves and sudden cardiac
arrest within minutes after
the administration of the drug in healthy appearing children (usually,
but not exclusively, males,
and most frequently 8 years of age or younger). There have also been
reports in adolescents.
Therefore, when a healthy appearing infant or child develops cardiac
arrest soon after
administration of succinylcholine not felt to be due to inadequate
ventilation, oxygenation, or
anesthetic overdose, immediate treatment for hyperkalemia should be
instituted. This should
include administration of intravenous calcium, bicarbonate, and
glucose with insulin, with
hyperventilation. Due to the abrupt onset of this syndrome, routine
resuscitative measures are
likely to be unsuccessful. However, extraordinary and prolonged
resuscitative efforts have
resulted in successful resuscitation in some reported cases. In
addition, in the presence of signs
of malignant hyperthermia, appropriate treatment should be instituted
concurrently.
Since there may be no signs or symptoms to alert the practitioner to
which patients are at risk, it is
recommended that the use of succinylcholine in children should be
reserved for emergency
intubation or instances where immediate securing of the airway is
necessary, e.g. laryngospasm,
difficult airway, full stomach, or for intramuscular use when a
suitable vein is inaccessible (see
PRECAUTIONS: PEDIATRIC USE and DOSAGE AND ADMINISTRATION).
THIS DRUG SHOULD BE USED ONLY BY INDIVIDUALS FAMILIAR WI